Development and Clinical Applications of Nucleic Acid Therapeutics
Identifieur interne : 002564 ( Main/Curation ); précédent : 002563; suivant : 002565Development and Clinical Applications of Nucleic Acid Therapeutics
Auteurs : Veenu Aishwarya [États-Unis] ; Anna Kalota [États-Unis] ; Alan M. Gewirtz [États-Unis]Source :
- Advances in Polymer Science [ 0065-3195 ]
Abstract
Abstract: In the past decade, our new understanding of post-transcriptional gene silencing (PTGS) has opened up new vistas that can help us to decipher the function of genes and thus to unravel the basic mechanistic principles and genetic networks in biology. This enormous potential of PTGS to selectively turn off genes either by antisense or RNA interference pathways has made a huge impact on research in basic science. Further, we can apply this knowledge and new set of rules in biomedical research for the development of more potent therapeutics. With a plethora of advantages of PTGS, there are still certain obstacles that need to be addressed to enable translation of this technology to the clinic. This article will focus on a brief history of the discovery and evolution of PTGS and its potential as a technology. We will also discuss the importance of target availability and some strategies for identification of the target sequence. Further, we will give an overview of some past experiences in the development of this technology in the clinic for cancer therapy, with a recent update on clinical development and trials on nucleic acid therapeutics.
Url:
DOI: 10.1007/12_2011_146
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000B75
- to stream Istex, to step Curation: Pour aller vers cette notice dans l'étape Curation :000B75
- to stream Istex, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000493
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :002589
Links to Exploration step
ISTEX:269031B1C37D96CF8E22831ED2E9B38F2955F420Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Development and Clinical Applications of Nucleic Acid Therapeutics</title><author><name sortKey="Aishwarya, Veenu" sort="Aishwarya, Veenu" uniqKey="Aishwarya V" first="Veenu" last="Aishwarya">Veenu Aishwarya</name></author><author><name sortKey="Kalota, Anna" sort="Kalota, Anna" uniqKey="Kalota A" first="Anna" last="Kalota">Anna Kalota</name></author><author><name sortKey="Gewirtz, Alan M" sort="Gewirtz, Alan M" uniqKey="Gewirtz A" first="Alan M." last="Gewirtz">Alan M. Gewirtz</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:269031B1C37D96CF8E22831ED2E9B38F2955F420</idno><date when="2011" year="2011">2011</date><idno type="doi">10.1007/12_2011_146</idno><idno type="url">https://api.istex.fr/ark:/67375/HCB-MLX9QK2F-X/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000B75</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000B75</idno><idno type="wicri:Area/Istex/Curation">000B75</idno><idno type="wicri:Area/Istex/Checkpoint">000493</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000493</idno><idno type="wicri:doubleKey">0065-3195:2011:Aishwarya V:development:and:clinical</idno><idno type="wicri:Area/Main/Merge">002589</idno><idno type="wicri:Area/Main/Curation">002564</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Development and Clinical Applications of Nucleic Acid Therapeutics</title><author><name sortKey="Aishwarya, Veenu" sort="Aishwarya, Veenu" uniqKey="Aishwarya V" first="Veenu" last="Aishwarya">Veenu Aishwarya</name><affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Hematology/Oncology, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA</wicri:regionArea><wicri:noRegion>PA</wicri:noRegion></affiliation><affiliation wicri:level="1"><country wicri:rule="url">États-Unis</country></affiliation></author><author><name sortKey="Kalota, Anna" sort="Kalota, Anna" uniqKey="Kalota A" first="Anna" last="Kalota">Anna Kalota</name><affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Hematology/Oncology, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA</wicri:regionArea><wicri:noRegion>PA</wicri:noRegion></affiliation></author><author><name sortKey="Gewirtz, Alan M" sort="Gewirtz, Alan M" uniqKey="Gewirtz A" first="Alan M." last="Gewirtz">Alan M. Gewirtz</name><affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Hematology/Oncology, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA</wicri:regionArea><wicri:noRegion>PA</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="s" type="main" xml:lang="en">Advances in Polymer Science</title><title level="s" type="abbrev">Advs Polymer Science</title><idno type="ISSN">0065-3195</idno><idno type="eISSN">1436-5030</idno><idno type="ISSN">0065-3195</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0065-3195</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: In the past decade, our new understanding of post-transcriptional gene silencing (PTGS) has opened up new vistas that can help us to decipher the function of genes and thus to unravel the basic mechanistic principles and genetic networks in biology. This enormous potential of PTGS to selectively turn off genes either by antisense or RNA interference pathways has made a huge impact on research in basic science. Further, we can apply this knowledge and new set of rules in biomedical research for the development of more potent therapeutics. With a plethora of advantages of PTGS, there are still certain obstacles that need to be addressed to enable translation of this technology to the clinic. This article will focus on a brief history of the discovery and evolution of PTGS and its potential as a technology. We will also discuss the importance of target availability and some strategies for identification of the target sequence. Further, we will give an overview of some past experiences in the development of this technology in the clinic for cancer therapy, with a recent update on clinical development and trials on nucleic acid therapeutics.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002564 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 002564 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= Main
|étape= Curation
|type= RBID
|clé= ISTEX:269031B1C37D96CF8E22831ED2E9B38F2955F420
|texte= Development and Clinical Applications of Nucleic Acid Therapeutics
}}
| This area was generated with Dilib version V0.6.33. |  |